ConMed
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 weeks.
- Recent price momentum is +2.6% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has fallen to 6.2% of float.
- Analyst tilt is Hold.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation B+
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 19.3x | Better than 44% |
| Forward P/E | 12.6x | Better than 66% |
| Price / Sales | 1.1x | Better than 75% |
| P/E vs own 5-yr range | 49th pctl | Better than 60% |
Growth A
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 9.6% | Better than 63% |
| Net income CAGR (3Y) | 28.4% | Better than 79% |
| Free cash flow CAGR (3Y) | 135.3% | Better than 96% |
Profitability C+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 54.6% | Better than 69% |
| Operating margin | 7.5% | Better than 43% |
| Net margin | 3.4% | Better than 38% |
| Return on equity | 4.7% | Better than 36% |
| Return on invested capital | 3.6% | Better than 39% |
Momentum B+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -8.8% | Better than 53% |
| 6-month return | 25.1% | Better than 87% |
| 12-month return (ex latest month) | 15.1% | Better than 53% |
| Distance below 52-week high | 15.0% | Better than 71% |
Financial Health B
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.1x | Better than 59% |
| Debt to assets | 35.9% | Better than 32% |
| Interest coverage | 3.3x | Better than 47% |
| Free cash flow / net income | 320.7% | Better than 87% |
Analyst View F
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 0.0% | Better than 0% |
| Upside to average target | 6.3% | Better than 10% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 46.38
- Open
- 46.11
- Day range
- 45.94 - 48.00
- Avg price
- 46.53
- Volume
- 384.32K
- Turnover
- 17.88M
- Turnover ratei
- 1.30%
- Volume ratioi
- 1.15
- Amplitudei
- 4.44%
- 52-week rangei
- 31.44 - 54.80
Valuation
- P/Ei
- 30.83
- P/E (TTM)i
- 19.32
- P/Bi
- 1.31
- EPSi
- 1.51
- Book value / shi
- 35.56
- Net profit
- 45.00M
- Net assets
- 1.06B
Share structure
- Market cap
- 1.39B
- Float capi
- 1.37B
- Shares out
- 29.80M
- Float sharesi
- 29.51M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
15.0% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+2.66M net over the window
Short interest
- Shares short
- 1.86M
- % of floati
- 6.24%
- Days to coveri
- 4.29
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of ConMed (CNMD)?
ConMed last traded at 46.56. This page shows a periodic quote snapshot. Check the displayed quote time.
What is ConMed's market cap?
About 1.39B.
What is the P/E ratio of ConMed?
The trailing twelve-month P/E is 19.32, above its own 5-year average of 19.26 — in the middle of its historical range (48.64% percentile). See the Valuation tab for the full history.
Does ConMed pay a dividend?
ConMed does not currently pay a regular dividend.
Is ConMed a buy according to analysts?
The consensus of 3 analysts is a Hold rating, with an average 12-month price target of 49.50, which implies 6.3% upside from the current price. This is not investment advice.
What is ConMed's StockVane Quant Rating?
The StockVane Momentum strategy currently rates ConMed a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
ConMed discussion 0 comments